James Debono, Dustin Balzan, John Joseph Borg, Stephen Falzon, Dania Al-Haddad, Benjamin Micallef, Janet Sultana
Nivolumab is used to treat several different types of cancers. Although it is generally considered to be effective and well-tolerated, it has been associated with adverse effects requiring discontinuation of treatment, like many other drugs used for cancer. A 70-year-old male was switched from sunitinib to nivolumab for renal cell carcinoma. The patient developed persistent hypothyroidism, onycholysis, and pneumonitis at nivolumab cycle 6, 10, and 11, respectively. Using the Naranjo causality method, the likelihood of causality was deemed "probable" for pneumonitis and hypothyroidism and "possible" for onycholysis...
April 2024: Journal of Pharmacy Technology: JPT: Official Publication of the Association of Pharmacy Technicians